Establishment and characterization of novel highly aggressive HER2 ‑positive and triple‑negative breast cancer cell lines

In conclusion, PC‑B‑142CA can serve as a novel HER2‑positive breast cancer cell line for drug resistance studies; while PC‑B‑148CA is a novel TN breast cancer cell line suitable for metastatic and stemness‑related properties.PMID:34651665 | DOI:10.3892/or.2021.8205
Source: Oncology Reports - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: KN026, a HER2 bispecific antibody, was well tolerated and achieved comparable efficacy as trastuzumab and pertuzumab doublet even in the more heavily pretreated patients. Co-amplification of HER2/CDK12 may define patients who benefit more from KN026.PMID:34844975 | DOI:10.1158/1078-0432.CCR-21-2827
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
Clin Breast Cancer. 2021 Oct 25:S1526-8209(21)00301-3. doi: 10.1016/j.clbc.2021.10.007. Online ahead of print.ABSTRACTEndocrine therapy (ET) for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (MBC) has changed markedly over recent years with the emergence of new ETs and the use of molecularly targeted agents. Cytotoxic chemotherapy continues, however, to have an important role in these patients and it is important to maximize its efficacy while minimizing toxicity to optimize outcomes. This review examines curre...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: KN026, a HER2 bispecific antibody, was well tolerated and achieved comparable efficacy as trastuzumab and pertuzumab doublet even in the more heavily pretreated patients. Co-amplification of HER2/CDK12 may define patients who benefit more from KN026.PMID:34844975 | DOI:10.1158/1078-0432.CCR-21-2827
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research
J Chemother. 2021 Nov 30:1-8. doi: 10.1080/1120009X.2021.2009722. Online ahead of print.ABSTRACTThe choice of the anti-HER2 agent depends on country-specific availability, the specific, previously administered anti-HER2 therapy and the relapse-free interval, although there is not much published data on the use of lapatinib after progression on pertuzumab and/or T-DM1. The aim of this research is to determine efficacy of lapatinib in this setting. This research included 111 patients with metastatic HER2 positive breast cancer who received lapatinib with capecitabine at The Oncology Institute of Vojvodina. Lapatinib was give...
Source: Journal of Chemotherapy - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: KN026, a HER2 bispecific antibody, was well tolerated and achieved comparable efficacy as trastuzumab and pertuzumab doublet even in the more heavily pretreated patients. Co-amplification of HER2/CDK12 may define patients who benefit more from KN026.PMID:34844975 | DOI:10.1158/1078-0432.CCR-21-2827
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
Clin Breast Cancer. 2021 Oct 25:S1526-8209(21)00301-3. doi: 10.1016/j.clbc.2021.10.007. Online ahead of print.ABSTRACTEndocrine therapy (ET) for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (MBC) has changed markedly over recent years with the emergence of new ETs and the use of molecularly targeted agents. Cytotoxic chemotherapy continues, however, to have an important role in these patients and it is important to maximize its efficacy while minimizing toxicity to optimize outcomes. This review examines curre...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
Contributors : Tong Liu ; Cheng Liu ; Jing Zhang ; Xiaofan Wei ; Hongquan ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe diverse cell types in the breast cancer microenvironment regulate tumor cell growth, metastasis, and response to therapy. However, little is known about the microenvironment of lymph node metastasis (LNM). Using single-cell transcriptome analysis together with T-cell receptor (TCR) sequencing, we generated single-cell maps of breast cancers and paired LNM in 8 patients. The T cells in LNM were relatively inactive, with weaker expansion and transition abili...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Study